User profiles for Vladimir Tolmachev
 | Vladimir TolmachevProfessor of biomedical radiation sciences, Uppsala University Verified email at igp.uu.se Cited by 16490 |
[HTML][HTML] Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications
J Löfblom, J Feldwisch, V Tolmachev, J Carlsson… - FEBS letters, 2010 - Elsevier
Affibody molecules are a class of engineered affinity proteins with proven potential for
therapeutic, diagnostic and biotechnological applications. Affibody molecules are small (6.5kDa) …
therapeutic, diagnostic and biotechnological applications. Affibody molecules are small (6.5kDa) …
Tumor imaging using a picomolar affinity HER2 binding affibody molecule
…, C Widström, J Carlsson, V Tolmachev… - Cancer research, 2006 - AACR
The detection of cell-bound proteins that are produced due to aberrant gene expression in
malignant tumors can provide important diagnostic information influencing patient …
malignant tumors can provide important diagnostic information influencing patient …
Selection and characterization of HER2/neu-binding affibody ligands
…, E Gunneriusson, V Tolmachev… - Protein Engineering …, 2004 - academic.oup.com
Affibody® (affibody) ligands that are specific for the extracellular domain of human epidermal
growth factor receptor 2 (HER2/neu) have been selected by phage display technology from …
growth factor receptor 2 (HER2/neu) have been selected by phage display technology from …
Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In-or 68Ga-labeled affibody molecules
…, A Orlova, A Wennborg, V Tolmachev… - Journal of nuclear …, 2010 - Soc Nuclear Med
The clinical utility of a human epidermal growth factor receptor 2 (HER2)–targeting Affibody
molecule for detection and characterization of HER2-positive lesions was investigated in …
molecule for detection and characterization of HER2-positive lesions was investigated in …
First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule
…, A Wennborg, J Feldwisch, V Tolmachev… - Journal of nuclear …, 2014 - Soc Nuclear Med
The expression status of human epidermal growth factor receptor type 2 (HER2) predicts
the response of HER2-targeted therapy in breast cancer. ABY-025 is a small reengineered …
the response of HER2-targeted therapy in breast cancer. ABY-025 is a small reengineered …
Radionuclide Therapy of HER2-Positive Microxenografts Using a 177Lu-Labeled HER2-Specific Affibody Molecule
A radiolabeled anti-HER2 Affibody molecule (Z HER2:342 ) targets HER2-expressing xenografts
with high selectivity and gives good imaging contrast. However, the small size (∼7 kDa…
with high selectivity and gives good imaging contrast. However, the small size (∼7 kDa…
[HTML][HTML] Measuring HER2-receptor expression in metastatic breast cancer using [68Ga] ABY-025 Affibody PET/CT
…, A Wennborg, J Feldwisch, V Tolmachev… - Theranostics, 2016 - ncbi.nlm.nih.gov
Purpose: Positron Emission Tomography (PET) imaging of HER2 expression could potentially
be used to select patients for HER2-targed therapy, predict response based on uptake …
be used to select patients for HER2-targed therapy, predict response based on uptake …
Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors
The Affibody molecule Z HER2:342-pep2 , site-specifically and homogeneously conjugated
with a 1,4,7,10-tetra-azacylododecane-N,N′,N″,N‴-tetraacetic acid (DOTA) chelator, was …
with a 1,4,7,10-tetra-azacylododecane-N,N′,N″,N‴-tetraacetic acid (DOTA) chelator, was …
[HTML][HTML] Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain
The therapeutic and diagnostic efficiency of engineered small proteins, peptides, and
chemical drug candidates is hampered by short in vivo serum half-life. Thus, strategies to tailor …
chemical drug candidates is hampered by short in vivo serum half-life. Thus, strategies to tailor …
Design of an optimized scaffold for affibody molecules
J Feldwisch, V Tolmachev, C Lendel, N Herne… - Journal of molecular …, 2010 - Elsevier
Affibody molecules are non-immunoglobulin-derived affinity proteins based on a three-helical
bundle protein domain. Here, we describe the design process of an optimized Affibody …
bundle protein domain. Here, we describe the design process of an optimized Affibody …